Rayzebio Inc 's Quick Ratio

RYZB's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth

Rayzebio Inc 's Cash & cash equivalent grew by 81.91 % in the Q3 2023 sequentially, faster than Current Liabilities, this led to improvement in Rayzebio Inc 's Quick Ratio to 34.09 a new company high.

Within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Quick Ratio than Rayzebio Inc in third quarter 2023. While Quick Ratio total ranking in the third quarter 2023 has deteriorated compared to the prior quarter from to 99.

Explain Quick Ratio?
How much Cash & cash equivalents RYZB�s has?
What are RYZB�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

RYZB Quick Ratio	(Sep 30 2023) Q3	(Dec 31 2022) Q3
Y / Y Current Liabilities Change	-	-	-	-	-
Y / Y Cash & cash equivalent Change	-	-	-	-	-
Quick Ratio MRQ	34.09	31.88	-	-	-
RYZB's Total Ranking	# 99	#	#	#	#
Seq. Current Liabilities Change	70.14 %	-	-	-	-
Seq. Cash & cash equivalent Change	81.91 %	-	-	-	-

Quick Ratio third quarter 2023 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 15
Healthcare Sector	# 20
Overall Market	# 99

Quick Ratio Statistics
High	Average	Low
34.09	32.98	31.88
(Sep 30 2023)		(Dec 31 2022)

Financial Statements
Rayzebio Inc 's Current Liabilities	$ 16 Millions	Visit RYZB's Balance sheet
Rayzebio Inc 's Cash & cash equivalent	$ 540 Millions	Visit RYZB's Balance sheet
Source of RYZB's Sales		Visit RYZB's Sales by Geography

Cumulative Rayzebio Inc 's Quick Ratio

RYZB's Quick Ratio for the trailling 12 Months

RYZB Quick Ratio	(Sep 30 2023) 12 Months	(Dec 31 2022) 12 Months	12 Months	12 Months	12 Months
Y / Y Current Liabilities TTM Growth	-	-	-	-	-
Y / Y Cash & cash equivalent TTM Growth	-	-	-	-	-
Quick Ratio TTM	33.27	31.88	-	-	-
Total Ranking TTM	#	#
Seq. Current Liabilities TTM Growth	170.14 %	-	-	-	-
Seq. Cash & cash equivalent TTM Growth	181.91 %	-	-	-	-

Quick ratio ranking by company, industry and sector >> Back to RYZB Financial Strength Comparisons >> Go to Compare RYZB Quick Ratio to its Competitors

On the trailing twelve months basis RYZB Cash & cash equivalent soared by 81.91 % in Q3 2023 year on year, faster than Current Liabilities, this led to increase in in Rayzebio Inc 's Quick Ratio to 33.27, above RYZB average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 14 other companies have achieved higher Quick Ratio than Rayzebio Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the third quarter 2022 from to 0.

Explain Quick Ratio?
How much Cash & cash equivalents RYZB�s has?
What are RYZB�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 15
Healthcare Sector	# 20
Within the Market	# 99

trailing twelve months Quick Ratio Statistics
High	Average	Low
34.09	32.98	31.88
(Sep 30 2023)		(Dec 31 2022)

Companies with similar Quick Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry	Quick Ratio	Sep 30 2023 MRQ Cash & cash equivalent	Sep 30 2023 MRQ Current Liabilities
Inhibitor Therapeutics Inc	60.98	$ 9.538 Millions	$ 0.156 Millions
Moonlake Immunotherapeutics	48.12	$ 495.979 Millions	$ 10.308 Millions
Third Harmonic Bio Inc	46.52	$ 273.892 Millions	$ 5.888 Millions
Altimmune inc	46.22	$ 140.779 Millions	$ 3.046 Millions
Neurogene Inc	42.92	$ 156.999 Millions	$ 3.658 Millions
Arca Biopharma Inc	38.80	$ 38.487 Millions	$ 0.992 Millions
Nuvation Bio Inc	38.37	$ 619.339 Millions	$ 16.143 Millions
Merrimack Pharmaceuticals Inc	38.34	$ 18.904 Millions	$ 0.493 Millions
Xbiotech Inc	38.19	$ 202.191 Millions	$ 5.294 Millions
Morphic Holding inc	37.57	$ 725.067 Millions	$ 19.298 Millions
Climb Bio Inc	37.03	$ 107.433 Millions	$ 2.901 Millions
Royalty Pharma Plc	35.91	$ 941.748 Millions	$ 26.222 Millions
Adc Therapeutics Sa	34.58	$ 310.407 Millions	$ 8.977 Millions
Rayzebio Inc	34.09	$ 540.169 Millions	$ 15.847 Millions
Cymabay Therapeutics Inc	31.72	$ 438.778 Millions	$ 13.831 Millions
Atea Pharmaceuticals Inc	31.50	$ 595.126 Millions	$ 18.893 Millions
Greenwich Lifesciences Inc	30.76	$ 9.144 Millions	$ 0.297 Millions
Verona Pharma Plc	29.80	$ 257.366 Millions	$ 8.636 Millions
Aprea Therapeutics Inc	29.39	$ 25.354 Millions	$ 0.863 Millions
Theseus Pharmaceuticals Inc	29.29	$ 205.122 Millions	$ 7.003 Millions
Viking Therapeutics Inc	28.75	$ 376.241 Millions	$ 13.086 Millions
Karuna Therapeutics Inc	27.40	$ 1,341.510 Millions	$ 48.968 Millions
Atossa Therapeutics Inc	27.33	$ 94.141 Millions	$ 3.444 Millions
Disc Medicine Inc	25.70	$ 370.541 Millions	$ 14.416 Millions
Belite Bio Inc	24.27	$ 88.157 Millions	$ 3.633 Millions
Janux Therapeutics Inc	24.17	$ 349.712 Millions	$ 14.471 Millions
Bright Minds Biosciences Inc	24.16	$ 5.197 Millions	$ 0.215 Millions
Design Therapeutics Inc	23.48	$ 290.940 Millions	$ 12.390 Millions
Lixte Biotechnology Holdings Inc	23.08	$ 5.106 Millions	$ 0.221 Millions
Anixa Biosciences Inc	23.06	$ 46.773 Millions	$ 2.028 Millions

Date modified: 2026-08-31T17:00:24+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.